Figure 2.
Figure 2. The schema of S1608 is depicted. Patients with POD24 after bendamustine-rituximab induction therapy will be randomized to either the phosphatidylinositol 3-kinase inhibitor TG1202 plus obinutuzumab (Arm A), lenalidomide-obinutuzumab (Arm B), or R-CHOP (Arm C).

The schema of S1608 is depicted. Patients with POD24 after bendamustine-rituximab induction therapy will be randomized to either the phosphatidylinositol 3-kinase inhibitor TG1202 plus obinutuzumab (Arm A), lenalidomide-obinutuzumab (Arm B), or R-CHOP (Arm C).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal